Predicting Response to Androgen Deprivation Therapy and Resistance to Castration in Metastatic Prostate Cancer

Objective: We sought to identify predictive factors affecting time to castration resistance in metastatic prostate cancer patients receiving androgen deprivation therapy (ADT). Materials and Methods: We retrospectively evaluated 47 patients who received ADT with the diagnosis of metastatic prostate cancer. The patients\" age, International Society of Urological Pathology (ISUP) scores, baseline prostate specific antigen (PSA), alkaline phosphatase (ALP) value, prostate-specific membrane antigen (PSMA) tracer expression, represented by the maximum standardised uptake value (SUV max) at diagnosis, nadir PSA value, and time to resistance to ADT were recorded. Results: All patients included in the study were resistant to treatment with ADT. The mean age of the patients was 70.81 ± 1.15 years. The mean time to develop resistance to treatment after castration was 31.51 ± 4.9 months. In the correlation analysis, a significant negative correlation was detected between PSA, nadir PSA values and time to treatment resistance. The relationship between the SUVmax value of the primary prostate lesion, ALP value at the time of diagnosis and time to response to ADT developed was not significant. Conclusion: We found PSA values at diagnosis and nadir PSA values during follow-up to be predictive factors of treatment resistance in metastatic prostate cancer patients receiving ADT.